{"protocolSection":{"identificationModule":{"nctId":"NCT06479772","orgStudyIdInfo":{"id":"2021-06-051"},"organization":{"fullName":"GCS Ramsay Santé pour l'Enseignement et la Recherche","class":"OTHER"},"briefTitle":"Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.","officialTitle":"Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.","acronym":"ELIAS"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-10-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2024-03-31","type":"ACTUAL"},"studyFirstSubmitDate":"2023-12-15","studyFirstSubmitQcDate":"2024-06-27","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-27","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GCS Ramsay Santé pour l'Enseignement et la Recherche","class":"OTHER"},"collaborators":[{"name":"Vivactis M2Research","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Based on data from a series of patients who underwent screening mammography with a \"normal\" or \"benign\" first-reading result. The main objective of the study is to evaluate the possibilities of subtracting from the second reading of breast cancer screening a population of examinations for which the risk of discovering cancer is close to zero, using an AI system (here the MammoScreen™ system).","detailedDescription":"This is a retrospective multicenter study of mammography imaging data contained in the PACS (Picture Archiving and Communication System) of six radiology centers located in the Rhône, Puy de dôme, Cantal and Haute-Loire départements.\n\nIn order to be able to collect two-year follow-up data, the files analyzed will concern all women who received a screening mammogram during the years 2015, 2016, 2017, 2018 and 2019. More recent mammograms will be excluded."},"conditionsModule":{"conditions":["Breast Cancer Female"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":55589,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of real negatives","description":"Percentage of cases negatived by MammoScreen (considered benign by the system), and for which no cancer was detected at the end of the L2 (according to the different risk levels of the MammoScreen software - score from 1 to 10). We distinguish two sub-populations: L2- and L2+ with BDD- (in addition to L2-).","timeFrame":"Week 8"}],"secondaryOutcomes":[{"measure":"Percentage of real positives","description":"Percentage of MammoScreen-positive cases for which cancer was detected in L2 (according to the different risk levels of the MammoScreen software - score from 1 to 10).","timeFrame":"Week 8"},{"measure":"Percentage of false negatives","description":"Percentage of MammoScreen-positive cases with an L2 ultimately considered negative (L2- or L2 + with DBB-), for which interval cancer is detected (according to the different risk levels of the MammoScreen software - score from 1 to 10).","timeFrame":"Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women aged 50 to 74 participating in the organized screening campaign.\n* Having had a screening mammogram with a final L1 result of \"normal\" (ACR 1/ BI-RADS 1) or \"benign\" (ACR 2/ BI-RADS 2).\n* For which a second reading interpretation is available\n* Screening mammograms performed during the years 2015 to2019 (In order to have follow-up data (subsequent mammogram or information on the person's future)\n\nExclusion Criteria:\n\n- Mammography not performed as part of organized screening","healthyVolunteers":true,"sex":"FEMALE","genderBased":true,"genderDescription":"Female breast cancer","minimumAge":"50 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"As this was a retrospective exploratory study, with no prior hypothesis, the number of subjects required was not calculated.\n\nThe study population (n=55,000) represents, for the radiology practices concerned, all mammograms examined in second reading by the Auvergne Rhône Alpes regional cancer screening coordination center between 2015 and 2019.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Christophe TOURASSE, MD","affiliation":"Hôpital Privé Jean Mermoz","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hôpital Privé Jean Mermoz","city":"Lyon","zip":"69008","country":"France","geoPoint":{"lat":45.74848,"lon":4.84669}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}